Routine CYP2C19 Genotyping, Antiplatelet Prescription Changes, and Clinical Outcomes After PCI in Chinese Patients With Coronary Heart Disease: A Single‐Center Retrospective Study
Dan Niu, Mei Zhang, Hong Guan, Satabdi Datta Choudhury · 2026
Read Routine CYP2C19 Genotyping, Antiplatelet Prescription Changes, and Clinical Outcomes After PCI in Chinese Patients With Coronary Heart Disease: A Single‐Center Retrospective Study by Dan Niu, Mei Zhang, Hong Guan, Satabdi Datta Choudhury (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13618363.txt.
Description
Dan Niu and three colleagues review what happened when a Chinese hospital made CYP2C19 genotyping routine for heart patients receiving stents. The gene shapes how well clopidogrel, a blood-thinning staple after percutaneous coronary intervention, works, and doctors can switch patients to ticagrelor instead. The retrospective study covered three hundred sixty-four adults treated during 2023, all of them genotyped under the hospital's policy.
Prescribing flipped dramatically once results landed. Before testing, three quarters of patients were on ticagrelor and a quarter on clopidogrel; afterward the proportions nearly reversed, with over two hundred fifty patients switching one way and seventy the other. About half the cohort were intermediate metabolizers and about one in seven poor metabolizers. Clinical outcome data were sparse and incomplete, so the authors explicitly refuse causal claims and label event comparisons exploratory only.
Catalog record
| CREATOR | Dan Niu, Mei Zhang, Hong Guan, Satabdi Datta Choudhury |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |